Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.62 |
| ▸ | MAPT | P10636 | 7/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30879375 | 1.00 | MEN1 (0.62) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL1446664 | 0.84 | LMNA (0.62) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL29888811 | 0.84 | LMNA (0.62) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL2644891 | 0.84 | LMNA (0.62) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL29527091 | 0.83 | LMNA (0.69) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL4029870 | 0.83 | PDE7A (0.73) | MEN1KMT2AMAPTLMNAPDE7A | |
| SCHEMBL5565241 | 0.83 | HTT (0.60) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL2031919 | 0.82 | PDE7A (0.60) | MEN1KMT2AMAPTLMNAPDE7A | |
| SCHEMBL8395820 | 0.82 | LMNA (0.59) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL2028774 | 0.81 | LMNA (0.62) | MEN1KMT2AMAPTLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664029-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-12-02 | — | — | EP | disclosed |
| EP-1444210-B1 | QUNAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| US-20070232607-A1 | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases | BRADBURY ROBERT H | 2007-10-04 | — | — | US | disclosed |
| CN-1993349-A | Quinazoline derivatives as ERBB receptor tyrosine kinases | ASTRAZENECA AB (SE) | 2007-07-04 | — | — | CN | disclosed |
| US-20070082921-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-12 | — | — | US | disclosed |
| EP-1756088-A1 | QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| US-20070015743-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | disclosed |
| CN-1882572-A | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2006-12-20 | — | — | CN | disclosed |
| EP-1664029-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005118572-A1 | QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005026152-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
| US-20050043336-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | US | disclosed |
| EP-1444210-A1 | QUNAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040108-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015743-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ABL1, EGFR | MEN1 2379/4885KMT2A 1832/4885MAPT 3525/4885 |
| US-20050043336-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | MEN1 1212/4885KMT2A 1693/4885MAPT 4300/4885 |
| US-20070082921-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | MEN1 2352/4885KMT2A 1786/4885MAPT 4124/4885 |
| US-20070232607-A1 | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases | ERBB2, ERBB3, ERBB4 | MEN1 1605/4885KMT2A 2263/4885MAPT 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.